Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.
Type | Public | |
Founded | 2017 | |
HQ | New York, NY, US | Map |
Website | prevailtherapeutics.com |
USD | |
---|---|
Net income (Q2, 2020) | (22.1m) |
EBIT (Q2, 2020) | (22.2m) |
Market capitalization (26-Jan-2021) | 787.7m |
Closing stock price (26-Jan-2021) | 23.0 |
Cash (30-Jun-2020) | 111.1m |
EV | 687.3m |
USD | FY, 2017 |
---|---|
Debt/Equity | 1.7 x |
Debt/Assets | 0.3 x |
Financial Leverage | 5.5 x |
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2017.
Who are Prevail Therapeutics key executives?
Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.
How many employees does Prevail Therapeutics have?
Prevail Therapeutics has 48 employees.
Who are Prevail Therapeutics competitors?
Competitors of Prevail Therapeutics include Molecular Partners, Brii Biosciences and Nordic Nanovector.
Where is Prevail Therapeutics headquarters?
Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.
Where are Prevail Therapeutics offices?
Prevail Therapeutics has an office in New York.
How many offices does Prevail Therapeutics have?
Prevail Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies